Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
A phase II, multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid refractory acute GVHD. Carpenter, P., Lowder, J., Johnston, L., Frangoul, H., Khoury, H., Parker, P., Abonour, R., Westervelt, P., Dansey, R., Richard, S., Jerome, K., Corey, L., Anasetti, C. AMER SOC HEMATOLOGY. 2003: 712A
View details for Web of Science ID 000186536702634